Johnson & Johnson (JNJ)Share Price and News
About Johnson & Johnson
Johnson & Johnson is a multinational corporation focused on the development of medical devices, pharmaceuticals, and consumer health products. With over 130 years in operation, the company's diverse business segments contribute to its standing as a global healthcare leader. Its products are sold in over 175 countries, impacting millions of lives worldwide.
The company’s medical devices division is highly regarded, providing products ranging from surgical tools to diagnostic devices. Additionally, JNJ’s pharmaceutical segment, which includes immunology, oncology, and neuroscience treatments, plays a crucial role in global healthcare. The company is distinguished by its long-standing commitment to innovation and sustainability, as well as its consistent dividend growth, which appeals to long-term investors.
Johnson & Johnson Company History
Founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson, Johnson & Johnson began by producing sterile surgical products and quickly became a pioneer in medical supplies and consumer health products.
Early innovations included first commercially successful sterile surgical sutures in 1887, helping shape modern surgical practices. Over the next century, J&J expanded globally through both organic growth and strategic acquisitions of pharmaceutical and medical device companies such as Janssen, Ethicon, McNeil and Actelion. This diversification strengthened its footprint across healthcare segments ranging from prescription medicines and medical devices to consumer health brands. In 2023, the company completed the spin‑off of its consumer health business as Kenvue, allowing J&J to focus more intensely on pharmaceuticals and MedTech.
Johnson & Johnson has navigated numerous challenges over its long history, including public health crises like the 1918 influenza pandemic and COVID‑19, while also facing significant legal and ethical issues. These have included litigation over products such as talc‑based powders and legal settlements related to medical devices and pharmaceuticals.
Future Outlook of Johnson & Johnson (JNJ)
Johnson & Johnson’s future outlook is grounded in its diversified portfolio, robust innovation pipeline, and strategic focus on high‑growth healthcare segments. After spinning off its consumer health division (Kenvue), the company sharpened its focus on pharmaceuticals and medical technology — the higher‑margin engines of growth within its business. Analysts project moderate steady revenue and earnings growth over the next several years, supported by strong performance in oncology and immunology products and consistent R&D productivity.
In 2025, J&J reported solid financial results with strong sales in key drugs such as DARZALEX and TECVAYLI, while free cash flow and balance sheet strength remain robust, providing flexibility for further investment and shareholder returns. The company has also pursued strategic acquisitions like Halda Therapeutics to strengthen its oncology pipeline and expand into precision cancer treatments. Additionally, plans to spin off the orthopedics business into a standalone company aim to streamline operations and concentrate growth on high‑innovation areas.
Despite these positives, challenges persist. J&J faces ongoing patent expirations, legal liabilities — including thousands of talc‑related lawsuits — and drug pricing pressures in key markets. However, its broad portfolio, innovation trajectory and strong financial base position the company to pursue growth through new product launches and strategic M&A, while continuing to deliver dividends and buybacks. Analysts broadly expect continued mid‑single‑digit revenue growth with potential acceleration from new therapies and pipeline successes.
Is JNJ a Good Stock to Buy?
Whether Johnson & Johnson is a good stock to buy depends on an investor’s goals, tolerance for risk and investment horizon. From a long‑term, value‑oriented perspective, J&J is often viewed as a defensive healthcare leader with a strong balance sheet, consistent free cash flow, and a history of dividend increases spanning more than six decades. It offers exposure to pharmaceuticals and medical technology — sectors with more predictable demand compared with cyclical industries.
Analyst consensus tends toward a Moderate Buy, with average 12‑month price targets suggesting potential upside and a steady earnings growth trajectory. Morgan Stanley, for example, upgraded J&J to Overweight, citing confidence in future growth and a stronger earnings outlook through 2030. Financial forecasts also project expansion in both revenue and EPS over the next several years, driven by strong oncology sales and pipeline catalysts. J&J’s diversified revenue mix and leadership in high‑growth therapeutic areas add resilience, while its dividend yield offers an income component appealing to conservative investors.
However, risks remain. The company deals with ongoing litigation, particularly relating to talc products, and must contend with competitive pressures, patent expirations and regulatory challenges, all of which can impact valuations and sentiment. Additionally, growth may be more moderate than high‑flying tech peers, so investors seeking significant capital gains might find J&J better suited as a core, defensive holding rather than a rapid growth play. Overall, it typically appeals to long‑term, income‑oriented investors who value stability, diversified healthcare exposure and consistent cash returns.
Our Stock Analysis
Sorry, we couldn't find any posts. Please try a different search.
Frequently Asked Questions
Johnson & Johnson boasts an attractive dividend yield, typically ranging between 2.5% and 3.0%. The company has a strong track record of increasing its dividends annually, making it a popular choice for income-seeking investors.